Pignone - Eligibility for aspirin for primary prevention in men increases when cancer mortality benefit added
Recent data suggest that aspirin may also be effective for reducing cancer deaths. Would the possible combined health benefits of reducing heart attacks and cancer outweigh the risks of gastrointestinal bleeding and stroke for middle-aged men?
A research team, including UNC scientists, reports that including the positive effect of aspirin on cancer mortality influences the threshold for prescribing aspirin for primary prevention in men. The benefit of aspirin for cancer mortality prevention would help offset the risks and thus lower the age and increase the number of men for whom aspirin is recommended.
Their results were published in the June issue of the Journal of General Internal Medicine.
Michael Pignone, MD, MPH, and study lead author, says, “We found that including a risk reduction for cancer deaths had a substantial impact on the overall benefits of aspirin, especially for early middle-aged men from 45 to 55 years of age. Based on this effect, several million men who were not previously good candidates for aspirin prevention would now become eligible.
Dr. Pignone is professor of medicine and chief of the division of general internal medicine, and a member of UNC Lineberger Comprehensive Cancer Center.
The U.S. Preventive Services Task Force, of which Dr. Pignone is a recently appointed member, recommends aspirin for primary prevention in men “when the potential benefit of a reduction in myocardial infarctions outweighs the potential harm of an increase in gastrointestinal hemorrhage.” This recommendation was issued in 2009, before the potential benefits for cancer reduction were recognized.
Other authors are: Stephanie Earnshaw, PhD, and Cheryl McDade, Research Triangle Institute Health Solutions in Research Triangle Park, NC; and Mark Pletcher, MD, of the University of California, San Francisco.
Funding for the study was provided by Partnership for Prevention and the National Heart, Lung and Blood Institute (R21HL1122256-01) and the National Cancer Institute (K05CA 129166).
Date: June 4, 2013